New study (below) found that lower hemoglobin was the only prognostic factor for shorter survival.
Can Urol Assoc J. 2018 Apr 6. doi: 10.5489/cuaj.5108. [Epub ahead of print]
Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.
Yokom DW1, Stewart J2, Alimohamed NS3, Winquist E4, Berry S5, Hubay S6, Lattouf JB7, Leonard H8, Girolametto C6, Saad F9, Sridhar SS1.
Cabazitaxel is one of several treatment options available for patients with metastatic castration-resistant prostate cancer who have progressed on docetaxel. Little is known about clinical factors that influence prognosis or treatment response for patients receiving cabazitaxel. Identifying prognostic and predictive factors could contribute to the optimal selection of patients for treatment after docetaxel.
A retrospective review of patients enrolled on the cabazitaxel Canadian Early Access Program (C-EAP) was performed. Clinical factors were analyzed by univariable and multivariable Cox proportional hazards and logistic regression analysis to identify independent predictors of prognosis and response.
Forty-five patients from five centres in Canada were included in this study. On multivariable analysis, lower hemoglobin was associated with shorter survival. No other factors were independently associated with survival, prostate-specific antigen (PSA) response or primary PSA progression.
Clinical factors predicting survival or treatment response were not identified for men with castration-resistant prostate cancer receiving cabazitaxel. Larger studies may be necessary to identify clinical factors and biomarkers that identify whether patients should or should not receive cabazitaxel.
PMID: 29629866 DOI: 10.5489/cuaj.5108